Momenta

Investor Relations

NASDAQ: MNTA
Price
10.82
Change
- 0.04
Day High
11.00
Day Low
10.68
Volume
440,600
4:00 PM ET on Jan 27, 2015
Stock price graph

Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for oncology and autoimmune indications.

In July 2010, the Momenta’s lead product (developed in collaboration with Sandoz) was approved as the first generic version of Lovenox® (Enoxaparin Sodium Injection).  The company’s development pipeline includes a generic version of Copaxone® (glatiramer acetate), also in collaboration with Sandoz, biosimilars in collaboration with Baxter.    necuparanib (formerly M402), a novel oncology drug candidate currently undergoing testing in early phase human clinical trials, and a portfolio of novel autoimmune drug candidates.

View Annual Report and Proxy Material

View all »   RSSRecent Releases

Jan 21, 2015
Momenta Pharmaceuticals Announces Supreme Court Decision to Remand Generic Copaxone(R) Case Back to CAFC

Dec 1, 2014
Momenta Pharmaceuticals' Necuparanib Receives Fast Track Designation From the FDA for the Treatment of Patients With Metastatic Pancreatic Cancer

Dec 1, 2014
Momenta Pharmaceuticals Announces Acceptance of a Clinical Trial Application in Europe for M923, a Biosimilar Version of Humira(R)

Last Revised 6/12/2012